Related Experiment Video
Updated: Jul 5, 2026
13:19
Microarray-based Identification of Individual HERV Loci Expression: Application to Biomarker Discovery in Prostate Cancer
Published on: November 2, 2013
Biomarkers for early prostate cancer detection.
M Margreiter1, A Stangelberger, E Valimberti
1Department of Urology, Medical University of Vienna, Vienna, Austria.
Summary
Prostate-specific antigen (PSA) improved early prostate cancer detection but lacks specificity. New blood biomarkers are being investigated to better distinguish cancer from benign conditions and improve early detection.
Area of Science:
- Oncology
- Biochemistry
- Medical Diagnostics
Background:
- Prostate-specific antigen (PSA) discovery in the 1990s transformed early prostate cancer detection and patient monitoring.
- Despite its utility, PSA lacks specificity, leading to false positives due to elevated levels in benign prostate conditions.
- The need for more precise biomarkers is critical to reduce overdiagnosis and overtreatment of prostate cancer.
Purpose of the Study:
- To review emerging blood biomarkers for early prostate cancer detection.
- To identify novel markers that can differentiate malignant from benign prostate lesions.
- To find biomarkers that distinguish indolent from aggressive prostate cancer subtypes.
Main Methods:
- Literature review of scientific articles and research databases.
- Focused search on emerging blood biomarkers for prostate cancer.
- Analysis of studies investigating biomarker performance in early detection.
Main Results:
- Several promising blood biomarkers have been identified through recent biotechnological advancements.
- These emerging biomarkers are currently under investigation for their diagnostic accuracy.
- The reviewed literature highlights ongoing efforts to find more specific markers than PSA.
Conclusions:
- New blood biomarkers show potential for improving early prostate cancer detection accuracy.
- Enhanced specificity of novel markers could reduce false positives and unnecessary treatments.
- Continued research is essential to validate and implement these biomarkers in clinical practice.
